MLN-9708

Alternative_name

4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid; ixazomib
Description

MLN-9708 is a prodrug of Ixazomib citrate (MLN-2238). MLN-9708 is an orally bioavailable next-generation proteasome inhibitor (PI) with potential potent anticancer activity in both hematologic and solid tumor xenograft models with better pharmacokinetic and pharmacodynamic features than PS-341 (Cat. No. 1846).
CAS Number

1239908-20-3
Structure Available

Yes
Salt Form

No
Molecular Formula

C₂₀H₂₃BCl₂N₂O₉
Molecular Weight

517.12
Cell Permeable

Yes
Purity

≥98% by HPLC
Solubilities

DMSO
Handling

Protect from air and light
Tag Line

A next-generation proteasome inhibitor (PI)
Storage Condition

-20°C
Shipping Condition

gel pack
Shelf Life

36 months
PubChem CID

56844015
PubChem CID Link
SMILES

B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
InChi

InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1
InChi Key

MBOMYENWWXQSNW-AWEZNQCLSA-N
Data Sheet Link
MSDS Available

Yes